Results 91 to 100 of about 3,194,674 (312)

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Frontiers in Pharmacology
IntroductionAnxiety diagnoses have surged recently during and after the COVID-19 pandemic. Lorazepam is widely recognized for its efficacy in treatment of anxiety, as well as insomnia, etc.
Zhengkang Su, Zhengwei Huang, Xiaoyu Chen, Xiaoyu Chen, Xi Li   +4 more
doaj   +1 more source

Adverse event summary.

, 2014
aRelationship = possible, probable.bAction taken = medication permanently stopped.AE; adverse event; HC, healthy control; TEAE, treatment-emergent AE.
Jacqueline Durfee (535277), Niels Bergsland (105411), David Hojnacki (194323), Michael G. Dwyer (105423), Deepa P. Ramasamy (535276), Silva Markovic-Plese (234124), Cheryl Kennedy (356039), Fernando Dangond (535278), Bianca Weinstock-Guttman (105396), Robert Zivadinov (105393), Brooke Hayward (28860)   +10 more
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology
ObjectiveLaronidase is the first drug of enzyme replacement therapy approved for the treatment of mucopolysaccharidosis type I (MPS I). However, its adverse events (AEs) have not been investigated in real - world settings.
Zhuomiao Lin, Junling Xue, Meiqing Yang, Xihui Yu, Jiahong Zhong   +4 more
doaj   +1 more source

Material Adverse Change Clauses and Acquisition Dynamics [PDF]

Material-Adverse-Change clauses (MACs) are present in over 90% of acquisition agreements. These clauses are the outcome of extensive negotiation and exhibit substantial cross-sectional variation in the number and types of events that are excluded from ...
Antonio J. Macias, David J. Denis
core  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system

BMC Pharmacology and Toxicology
Background Cefotaxime has been widely used in the clinical treatment of infections. However, there is still a lack of systematic researches for the adverse event profiles of cefotaxime through large-scale post-marketing monitoring.
Cheng Jiang, Jiancheng Qian, Yingyan Lu, Junxian Zheng   +3 more
doaj   +1 more source

Adverse event incidence, praziquantel 40 mg/kg.

, 2014
Legend. ci, confidence interval.Adverse event incidence, praziquantel 40 mg/kg.
Piero L. Olliaro (217564), Julien Zwang (261429)   +1 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Number of adverse event ratings required for true probability of adverse event to exceed 50%, 75%, and 95%.

, 2012
This table enables the identification of the number of raters required to obtain a given certainty that a case ‘truly’ represents an adverse event. For example, if an investigator wished to be 95% certain a case represented an adverse event, then it ...
Carl van Walraven (149343), Alan J. Forster (149339), Monica Taljaard (118231), Carol Bennett (105950)   +3 more
core   +1 more source